Cut price Herceptin and MabThera in India could set Roche's emerging market strategy
This article was originally published in Scrip
Executive Summary
Roche will be partnering up with the Indian firm Emcure to launch reduced price versions of its anticancers Herceptin (trastuzumab) and MabThera (rituximab) in India. The move has nothing to do with India's decision to issue a compulsory license for Bayer's anticancer, Nexavar (sorafenib tosylate), but is instead more of a pilot for reaching lower income patients in emerging markets, the firm told Scrip.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.